DETAILS, FICTION AND TRASTUZUMAB BREAST CANCER

The most less than-investigated “driving forces” linked to trastuzumab resistance is PTEN. Nagata et al. (2004) documented that the lack of PTEN was observed in 36% of HER2-favourable Key breast tumor specimens from individuals with phase IV condition. In addition, Additionally they showed that clients with PTEN-deficient tumors experienced rem